FCF YoY
+16.45%
OCF YoY
+16.45%
Capex Change
+0.0
FCF Conversion Δ
—
Free cash flow bridge for SELLAS Life Sciences Group (SLS) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $5.55M
FCF bridge breakdown for SELLAS Life Sciences Group (SLS) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | −$33.71M | — |
| Operating Cash Flow | $5.55M | +100.0% |
| Capital Expenditure | $0.00 | 0.0% |
| Free Cash Outflow | −$28.16M | — |
- Prior Free Cash Flow−$33.71M
- Operating Cash Flow$5.55M
- Capital Expenditure$0.00
- Free Cash Outflow−$28.16M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement